| Quarterly Financials | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 681 | 916 | 852 | 895 | 935 | 1,216 | 1,132 | 1,109 | 1,168 | 931 | 1,110 | 1,000 | 824 | 1,246 | 1,427 | 1,583 | 1,580 | 1,453 | 1,466 | 1,443 | 1,469 | 1,563 |
| Expenses | 395 | 472 | 534 | 595 | 560 | 718 | 704 | 714 | 755 | 587 | 748 | 649 | 673 | 915 | 1,049 | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 | 1,077 | 1,138 |
| EBITDA | 286 | 445 | 318 | 299 | 375 | 498 | 428 | 395 | 414 | 344 | 363 | 351 | 151 | 332 | 377 | 394 | 401 | 316 | 357 | 418 | 392 | 425 |
| Operating Profit % | 38 % | 47 % | 36 % | 31 % | 37 % | 38 % | 35 % | 33 % | 32 % | 32 % | 28 % | 31 % | 14 % | 24 % | 24 % | 23 % | 23 % | 19 % | 21 % | 26 % | 24 % | 24 % |
| Depreciation | 24 | 24 | 25 | 25 | 25 | 25 | 26 | 28 | 31 | 35 | 37 | 38 | 38 | 65 | 81 | 105 | 93 | 92 | 94 | 96 | 96 | 101 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 2 | 5 | 6 | 5 | 10 | 6 | 6 | 23 | 7 | 12 |
| Profit Before Tax | 262 | 420 | 293 | 273 | 349 | 472 | 401 | 366 | 381 | 309 | 324 | 311 | 111 | 261 | 290 | 283 | 298 | 218 | 257 | 299 | 288 | 313 |
| Tax | 67 | 106 | 74 | 69 | 89 | 121 | 99 | 93 | 95 | 79 | 83 | 79 | 33 | 67 | 96 | 91 | 106 | 75 | 93 | 95 | 102 | 97 |
| Net Profit | 195 | 314 | 219 | 204 | 260 | 351 | 302 | 273 | 286 | 229 | 241 | 232 | 79 | 194 | 194 | 192 | 192 | 144 | 164 | 205 | 187 | 216 |
| EPS in ₹ | 12.57 | 20.24 | 14.12 | 12.83 | 15.93 | 21.41 | 18.37 | 16.62 | 17.40 | 13.93 | 14.65 | 14.08 | 4.78 | 11.79 | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 |
Gland Pharma
Gland Pharma
1,924.80
(%)
Key Fundamentals
Market Cap
31,712.30 Cr
EPS
42.40
PE Ratio
41.17
Dividend Yield
0.94 %
Industry
Healthcare 52 Week High
2,131.00
52 Week Low
1,277.80
PB Ratio
3.47
Debt to Equity
0.04
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from13 analysts
Actual
Company News
View All News
Gland Pharma Ltd. witnessed a block trade worth Rs. 45.99 crores on the NSE. The transaction involved approximately 240,922 shares at a price of Rs. 1,909.00 per share.
Cancer Medications May Be Excluded From GST
Sep 03, 2025
Sep 03, 2025There is a possibility that cancer medications might be excluded from GST. This development could impact Gland Pharma, a pharmaceutical company that operates in the cancer treatment segment.
Gland Pharma has received approval for Vasopressin in 5% Dextrose Injection. The market size for this product is $45 million.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,688.60 | #1 4,05,151.70 | 38.97 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 61.71 | |
6,604.00 | 1,75,315.50 | 76.01 | 9,712.00 | 18.67 | 2,191 | 26.74 | 72.60 | |
1,639.10 | 1,32,399.00 | 24.59 | 28,409.50 | 7.12 | 5,291 | 9.88 | 60.63 | |
3,570.40 | 1,20,838.60 | 60.35 | 11,539.40 | 6.99 | 1,911 | 19.91 | 53.74 | |
1,282.00 | 1,06,997.50 | #1 18.64 | 33,741.20 | 16.73 | 5,725 | 1.26 | 48.97 | |
2,455.10 | 1,01,336.30 | 52.95 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 47.04 | |
1,002.35 | 1,00,859.90 | 21.40 | 23,511.00 | 18.55 | 4,615 | 2.60 | 45.37 | |
1,943.80 | 88,783.90 | 23.86 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.82 | |
5,557.00 | 66,442.30 | 28.47 | 13,458.30 | 3.70 | 2,216 | 21.39 | 63.11 | |
1,099.40 | 63,853.30 | 19.02 | 32,345.60 | 9.43 | 3,484 | -10.24 | 50.87 |
Growth Rate
Revenue Growth
-0.08 %
Net Income Growth
-9.58 %
Cash Flow Change
-8.23 %
ROE
-13.79 %
ROCE
-8.55 %
EBITDA Margin (Avg.)
-1.28 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 4,086 | 6,496 | 7,834 | 8,778 | 10,661 | 11,225 |
| Fixed Assets | 968 | 954 | 1,502 | 1,571 | 3,947 | 4,147 |
| Current Assets | 2,846 | 5,124 | 5,852 | 6,901 | 5,645 | 6,783 |
| Capital Work in Progress | 189 | 338 | 191 | 177 | 238 | 151 |
| Investments | 0 | 0 | 155 | 0 | 0 | 0 |
| Other Assets | 2,930 | 5,204 | 5,986 | 7,030 | 6,477 | 6,927 |
| Total Liabilities | 4,086 | 6,496 | 7,834 | 8,778 | 10,661 | 11,225 |
| Current Liabilities | 359 | 513 | 582 | 729 | 1,398 | 1,565 |
| Non Current Liabilities | 81 | 80 | 94 | 90 | 539 | 509 |
| Total Equity | 3,646 | 5,903 | 7,158 | 7,959 | 8,724 | 9,151 |
| Reserve & Surplus | 3,631 | 5,887 | 7,141 | 7,942 | 8,707 | 9,134 |
| Share Capital | 16 | 16 | 16 | 17 | 17 | 17 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -67 | 323 | -174 | 1,590 | -1,552 | 2,199 |
| Investing Activities | -761 | -1,520 | -999 | 1,211 | -1,749 | 1,718 |
| Operating Activities | 701 | 605 | 791 | 364 | 997 | 915 |
| Financing Activities | -7 | 1,239 | 35 | 15 | -799 | -434 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 58.25 % | 58.14 % | 58.02 % | 58.00 % | 58.00 % | 57.87 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.00 % | 4.91 % | 0.00 % | 3.59 % | 6.88 % | 4.47 % | 5.04 % | 6.90 % | 7.39 % | 7.91 % |
| DIIs | 10.69 % | 11.57 % | 11.39 % | 11.21 % | 11.94 % | 16.71 % | 20.58 % | 23.13 % | 23.23 % | 23.38 % | 22.45 % | 23.14 % | 25.23 % | 32.83 % | 35.37 % | 34.80 % | 33.27 % | 32.85 % | 32.64 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 3.30 % | 3.72 % | 3.77 % | 3.58 % | 3.69 % | 3.70 % | 3.77 % | 4.02 % | 4.26 % | 5.60 % | 4.52 % | 3.79 % | 3.28 % | 3.33 % | 3.28 % | 3.30 % | 2.99 % | 2.91 % | 2.57 % |
| Others | 27.76 % | 26.58 % | 26.81 % | 27.21 % | 26.37 % | 21.71 % | 17.78 % | 14.98 % | 14.64 % | 13.16 % | 10.27 % | 15.22 % | 10.04 % | 5.12 % | 5.04 % | 5.04 % | 5.01 % | 5.02 % | 5.06 % |
| No of Share Holders | 84,467 | 98,203 | 1,09,326 | 1,09,097 | 1,09,098 | 1,17,339 | 1,27,879 | 1,48,469 | 1,50,578 | 1,81,747 | 1,61,627 | 1,36,021 | 1,22,375 | 1,22,665 | 1,22,358 | 1,21,075 | 1,13,788 | 1,10,671 | 97,151 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20 | 18 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26 | 0.94 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 03 Nov 2025 |  Quarterly Result Announcement | NA | 03 Nov 2025 | 1,917.60 | 1,924.80 |
| 16 Aug 2024 |  Dividend | ₹ 20.00 /share | 16 Aug 2024 | 1,800.25 | 1,958.25 |
| 30 Aug 2024 |  Annual General Meeting | NA | 30 Aug 2024 | 1,800.25 | 1,849.00 |
| 04 Nov 2024 | Quarterly Result Announcement | NA | 04 Nov 2024 | 1,675.30 | 1,644.85 |
| 03 Feb 2025 | Quarterly Result Announcement | NA | 03 Feb 2025 | 1,672.75 | 1,530.45 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 1,418.75 | 1,484.15 |
| 05 Aug 2025 | Quarterly Result Announcement | NA | 05 Aug 2025 | 2,000.80 | 1,982.80 |
| 14 Aug 2025 | Dividend | ₹ 18.00 /share | 14 Aug 2025 | 1,484.15 | 1,950.30 |
| 28 Aug 2025 | Annual General Meeting | NA | 28 Aug 2025 | 1,484.15 | 1,928.25 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation3 days ago
3 days agoBoard Meeting Intimation for Declaration Of Unaudited Financial Results For The Quarter And Half Year Ended September 30 20253 days ago
3 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20186 days ago
6 days agoClosure of Trading WindowSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 17, 2025
Sep 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 08, 2025
Sep 08, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 28, 2025
Aug 28, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateAug 28, 2025
Aug 28, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 28, 2025
Aug 28, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 28, 2025
Aug 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 25, 2025
Aug 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 18, 2025
Aug 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 11, 2025
Aug 11, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 05, 2025
Aug 05, 2025Board Meeting Outcome for Submission Of Unaudited Financial Results For The Quarter Ended June 30 2025Aug 05, 2025
Aug 05, 2025Unaudited Financial Results For The Quarter Ended June 30 2025Aug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Aug 01, 2025Rumour verification - Regulation 30(11)Aug 01, 2025
Aug 01, 2025Clarification sought from Gland Pharma LtdAug 01, 2025
Aug 01, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 31, 2025
Jul 31, 2025Notice Of 47Th AGM Of Gland Pharma LimitedJul 31, 2025
Jul 31, 2025Reg. 34 (1) Annual Report.Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 21, 2025
Jul 21, 2025Board Meeting Intimation for Declaration Of Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025Jul 21, 2025
Jul 21, 2025Gland Pharma Receives GMP Compliance Certificate From The Danish Medicines Agency For Aseptically Prepared Powder For Injection Infusion And InhalationJul 11, 2025
Jul 11, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Jul 11, 2025Grant Of Stock Options Under Gland Pharma Employee Stock Option Scheme 2025Jul 03, 2025
Jul 03, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Receipt Of EIR From US FDA For Companys JNPC Facility VisakhapatnamJun 24, 2025
Jun 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 23, 2025
Jun 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 19, 2025
Jun 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 13, 2025
Jun 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 09, 2025
Jun 09, 2025Update On ANSM Inspection At Cenexis Fontenay Manufacturing FacilityJun 04, 2025
Jun 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 04, 2025
Jun 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Jun 02, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 27, 2025
May 27, 2025Grant Of Stock Options (Grant I) Under Gland Pharma Employee Stock Option Scheme 2025 (ESOP 2025 Or Scheme)May 22, 2025
May 22, 2025Mutual Fund Holdings
DSP Small Cap Direct Plan-Growth 
ICICI Prudential Multicap Fund Direct Plan-Growth 
Bandhan Large & Mid Cap Fund Direct-Growth 
HDFC Manufacturing Fund Direct - Growth 
Sundaram Large and Mid Cap Fund Direct-Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
Aditya Birla Sun Life Quant Fund Direct-Growth 
Canara Robeco Manufacturing Fund Direct - Growth 
SBI Nifty Smallcap 250 Index Fund Direct - Growth 
Axis Nifty Smallcap 50 Index Fund Direct-Growth 
Motilal Oswal Nifty Midcap 150 Index Fund Direct - Growth 
Mirae Asset Midcap Fund Direct - Growth 
Mahindra Manulife Flexi Cap Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 44.48
ATR(14)
Less Volatile 46.98
STOCH(9,6)
Neutral 27.54
STOCH RSI(14)
Oversold 19.69
MACD(12,26)
Bearish -4.92
ADX(14)
Weak Trend 11.77
UO(9)
Bearish 46.75
ROC(12)
Downtrend And Accelerating -2.87
WillR(14)
Oversold -84.56
About Gland Pharma
Gland Pharma Limited is an Indian generic injectables manufacturer specializing in sterile injectables, oncology, and ophthalmic products. Founded in 1978, the company operates primarily on a B2B model, selling products in over 60 countries. It has 8 manufacturing facilities in India, including 4 for finished formulations and 3 for APIs. The company has 284 ANDA filings in the US, with 234 approved. It expanded its business to include contract development, dossier preparation, and technology transfer. In 2023, Gland Pharma acquired Cenexi through its Singapore subsidiary, adding 7 new subsidiaries. The company offers various delivery systems and key molecules such as Heparin Sodium and Enoxaparin Sodium Injections.
Listing Date
20 Nov, 2020(4 Years,
31 days)
Website
Chairperson NameSRINIVAS SADU
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
